Aktienanalyse zu The Oncology Institute, Inc. (STLN)STLNThe Oncology Institute, Inc.

Starling Oncology, Inc., formerly The Oncology Institute, Inc., is advancing oncology by delivering specialized, value-based cancer care in the community setting. The Company offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with oncology organizations. Its critical services include cancer treatment and infusion centers, in-house dispensary, lab testing, outpatient blood transfusion, financial counseling, end-of-life counseling and comprehensive clinical trials. It treats many forms of cancer, including Acute lymphoblastic leukemia; Acute myeloid leukemia; Bladder cancer; Bone cancer; Brain cancer; Cervical cancer; Choriocarcinoma; Chronic lymphocytic leukemia (CLL); Chronic myeloid leukemia (CML); Skin cancer, and others. It operates over 100 clinics and affiliate locations across multiple states.

Starling Oncology, Inc. appears to be a good buy right now, especially considering its recent performance and growth trajectory. The current price is $6.71, which is well below the projected upper band of $7.34 based on Fibonacci levels, indicating potential for upward movement. Additionally, the stock has shown a year-to-date change of +30.80%, reflecting strong momentum. However, the main risk is the negative net income, which was -$9,789,000 in Q2 2026, indicating ongoing financial challenges that investors should monitor closely.